M
Matthew A. Rank
Researcher at Mayo Clinic
Publications - 148
Citations - 2869
Matthew A. Rank is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Asthma & Medicine. The author has an hindex of 25, co-authored 119 publications receiving 2019 citations. Previous affiliations of Matthew A. Rank include University of Rochester & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
IL-33–activated dendritic cells induce an atypical TH2-type response
Matthew A. Rank,Takao Kobayashi,Hideaki Kozaki,Kathleen R. Bartemes,Diane L. Squillace,Hirohito Kita +5 more
TL;DR: In this paper, the IL-33-activated dendritic cells (DCs) responded to IL-1 and showed that IL-3-activated DCs prime naive CD4 + T cells to produce T H 2-type cytokines.
Journal ArticleDOI
AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis
Ikuo Hirano,Edmond S. Chan,Matthew A. Rank,Rajiv N. Sharaf,Neil Stollman,David R. Stukus,Kenneth K. Wang,Matthew Greenhawt,Yngve T. Falck-Ytter,Karen A. Chachu,Lukejohn W. Day,Benjamin Lebwohl,Thiruvengadam Muniraj,Amit Patel,Anne F. Peery,Raj C. Shah,Harminder Singh,Siddharth Singh,Stuart J. Spechler,Shahnaz Sultan,Grace L. Su,Aaron P. Thrift,Jennifer M. Weiss,Adam V. Weizman,Jonathan A. Bernstein,Chitra Dinakar,David B.K. Golden,David A. Khan,Jay A. Lieberman,John Oppenheimer,Marcus Shaker,Dana Wallace,Julie Wang,Glenn T. Furuta,Evan S. Dellon,Jonathan M. Spergel,Seema S. Aceves,Yngve Falck-Ytter,Rajiv N. Sharaf +38 more
Journal ArticleDOI
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach.
Matthew Greenhawt,Elissa M. Abrams,Marcus Shaker,Derek K. Chu,David A. Khan,Cem Akin,Waleed Alqurashi,Peter D. Arkwright,James L. Baldwin,Moshe Ben-Shoshan,Jonathan A. Bernstein,Theresa Bingemann,Katharina Blumchen,Aideen Byrne,Antonio Bognanni,Dianne E. Campbell,Ronna L. Campbell,Zain Chagla,Edmond S. Chan,Jeffrey Chan,Pasquale Comberiati,Timothy E. Dribin,Anne K. Ellis,David Fleischer,Adam T. Fox,Pamela A. Frischmeyer-Guerrerio,Remi Gagnon,Mitchell H. Grayson,Caroline C. Horner,Jonathan Hourihane,Constance H. Katelaris,Harold Kim,John M. Kelso,David M. Lang,Dennis K. Ledford,Michael Levin,Jay A. Lieberman,Richard Loh,Doug Mack,Bruce Mazer,Giselle Mosnaim,Daniel Munblit,S. Shahzad Mustafa,Anil Nanda,John Oppenheimer,Kirsten P Perrett,Allison Ramsey,Matthew A. Rank,Kara Robertson,Javed Sheikh,Jonathan M. Spergel,David R. Stukus,Mimi L.K. Tang,James M. Tracy,Paul Turner,Anna Whalen-Browne,Dana Wallace,Julie Wang,Susan Waserman,John K. Witry,Margitta Worm,Timothy K. Vander Leek,David B.K. Golden +62 more
TL;DR: In this article, a multidisciplinary group of international experts in anaphylaxis composed of allergy, infectious disease, emergency medicine, and front-line clinicians to systematically develop recommendations regarding SARS-CoV-2 vaccine immediate allergic reactions.
Journal ArticleDOI
Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update.
Mark S. Dykewicz,Dana Wallace,Fuad M. Baroody,Jonathan A. Bernstein,Timothy J. Craig,Ira Finegold,Faith Huang,Désirée Larenas-Linnemann,Eli O. Meltzer,Gary C. Steven,David I. Bernstein,Joann Blessing-Moore,Chitra Dinakar,Matthew Greenhawt,Caroline C. Horner,David A. Khan,David M. Lang,John Oppenheimer,Jay M. Portnoy,Christopher Randolph,Matthew A. Rank +20 more
TL;DR: The updated Rhinitis Workgroup literature search initially cast a large net for all articles published in regard to rhinitis and treatment with the therapies under consideration, and found 4,059 references that failed tomeet the inclusion criteria, of which 59 unique trials were identified of which 13 reference articles were used to address the 3 questions in the current systematic review.
Journal ArticleDOI
The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials
Matthew A. Rank,John B. Hagan,Miguel A. Park,Jenna C. Podjasek,Shefali Samant,Gerald W. Volcheck,Patricia J. Erwin,Colin P. West +7 more
TL;DR: In this article, the risk of asthma exacerbation in patients who stop low-dose inhaled corticosteroids (ICSs) compared with those who continue ICSs in randomized controlled trials was estimated.